One taker in four years, but MHRA/NICE persist on parallel advice
This article was originally published in Scrip
Regulators and health technology assessors in the UK are trying to breathe life into a program that is aimed at providing drug companies with parallel scientific advice on their product development plans but which has only been used once in the more than four years it has been available.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The European public assessment report for Novartis's advanced breast cancer therapy, Piqray (alpelisib), includes some interesting insights into what EU regulators are looking for in drug company clinical trials.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.